Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Merger or Acquisition (September 2025)
18 slides from Poly Medicure's merger presentation, Sep 3, 2025
Slide 1: Submission of Investor's Presentation on Acquisition of Pendracare Group
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 (INDIA) 1:» IPOLYMED ~+91 - 11 - 33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN : L40300Dll995PLC066923 Date: 03 rd September, 2025 Scrip Code: - 531768 Scrip Code:- POL
Slide 2: Acquisition of Pendracare Group
Acquisition of Pendracare Group A unique interventional cardiology consumable asset in Europe Investor Presentation September 2025
Slide 3: Polymed: India's Leading MedTech Company
Polymed : India’s Leading MedTech Company
Slide 4: Polymed at a Glance
Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ Countries 200+ Medical Devices 3000+ Employee Base 530+ Sales Associates 334 Patents Granted 900+ Distributors across 1.8 Billion+ Devices Manufacturing Capacity India & Globally Per year 3
Slide 5: Navigating the Path & beyond
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 6: Our Innovations Deliver Care to Key Clinical Specialties
Our Innovations Deliver Care to Key Clinical Specialties Cardiology Anaesthesia & Respiratory Care Transfusion System Oncology Vascular Access Infusion Therapy Gastroenterology Diagnostics Urology Dialysis & Renal Care Surgery & Wound Drainage Critical Care 5
Slide 7: Polymed's Ecosystem (Manufacturing Process)
Polymed’s Ecosystem (Manufacturing Process) Clinical Support Distribution Network on Sales & Marketing u t i ri b D ist Product Concept Product Product Design Manufacturing Rapid Prototyping De Product Packaging ve t ion lop Regulatory me duc nt Pr o Sterilization Compliance Tool Design Tool Manufac
Slide 8: Polymed's Manufacturing Footprint
Polymed's Manufacturing Footprint 12 Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India SEZ 2, Jaipur, India Laiyang-qingdao, 104-105,Faridabad Amaro, Italy Haridwar Plant, India IMT 2, Faridabad 115-116, Faridabad SEZ 1 Jaipur, India R & D Centre, India Assuit, Egypt China P
Slide 9: Way Forward
Way Forward Research & Development § Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations Emphasizing Inorganic Growth § Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expanding market reac
Slide 10: Robust Growth Backed by Solid Balance Sheet
Robust Growth Backed by Solid Balance Sheet… Amount in INR Cr. Total Income EBITDA# Op, EBITDA Margin PAT PAT Margin 1800 R 1,670 600 27% 500 21% CAG 20% % 1600 22 500 26% 26% 1,376 453 400 19% 1400 339 1200 1,115 400 24% 358 923 23% 300 16% 258 1000 16% 300 265 800 213 179 200 600 200 147 445 400 1
Slide 11: PendraCare: Unique interventional cardiology asset
PendraCare : Unique interventional cardiology asset
Slide 12: Executive Summary
Executive Summary • Located at Leek (Netherlands), specializing in cardiology catheter-based technologies • One of the few fully integrated independent player of size and scale in Europe in its space • Develops, manufactures and sells innovative catheter solutions; also provide design, development a
Slide 13: Pendracare – A Unique Interventional Cardiology consumable business in Europe
Pendracare – A Unique Interventional Cardiology consumable business in Europe Pendracare – One-of-a-kind opportunity With diversified revenue base Backed by strong management Core Business Split, CY24 Sander Hartman – Located in Leek Netherlands CEO / Founder Guiding In Pendracare since 2012 OEM cat
Slide 14: Well Established Products with regulatory approvals in key markets
Well Established Products with regulatory approvals in key markets Product Description Photos OEM Distributor • CE marked & FDA approved Guiding Catheter • 2.5-year ARCUS-IMPROVE clinical data ✔ ✔ (GC) • Radial access design: hydrophilic coating & support Diagnostic Catheter • CE marked ✔ ✔ (DC) • S
Slide 15: Manufacturing Facility
Manufacturing Facility Leek, Netherlands ISO 13485 and FDA approved manufacturing 3,800 m2 Leased facility (across 3 locations) 1,150 m2 Cleanroom >1.5 million production capacity per year New lease signed ~2300m2 for consolidating operations at one location; transition expected in CY 2028 14
Slide 16: Significant synergies potential and platform for global expansion of cardiology business
Significant synergies potential and platform for global expansion of cardiology business 1 2 3 4 Manufacturing Expansion of Leverage Direct access to and Procurement Distribution existing European Synergy Network relationships market Cost synergies Expanding sales Leveraging Deepening expected in th
Slide 17: Transaction rationale - Strategic asset provides platform for expansion
Transaction rationale - Strategic asset provides platform for expansion of cardiology business globally Strategic Asset § One of the few independent cardiology Existing relationships with key global med-tech consumable business in Europe customers § Fits well with Polymed’s strategy to § Established
Slide 18: Thank You
Poly Medicure Limited Registered Office: Thank You 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com 17
Poly Medicure — Merger or Acquisition (September 2025) on 6ix